Natus Medical Board of Directors Strengthens Governance and Focuses on Growth

Rhea-AI Summary

Natus Medical Incorporated (NASDAQ: NTUS) announced the establishment of an Environmental, Social & Governance (ESG) committee and the transition of its Quality & Compliance Committee to the Innovation & Quality Committee as of September 30, 2021. The ESG committee will oversee sustainability and transparency in reporting, while the Innovation & Quality committee aims to enhance product innovation and quality. Thomas J. Sullivan has been appointed as Senior Independent Director, reflecting the company's commitment to strong governance and strategic growth initiatives.

Positive

• Establishment of the ESG committee to enhance sustainability and transparency.
• Transition to the Innovation & Quality committee aimed at boosting product growth and compliance.
• Appointment of Thomas J. Sullivan adds experienced leadership to the board.

Negative

• None.

• Establishes Environmental, Social & Governance Committee
• Transitions Quality & Compliance Committee to Innovation & Quality Committee
• Names Thomas J. Sullivan Senior Independent Director
  

PLEASANTON, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company’s Board of Directors established an Environmental, Social, and Governance (ESG) committee and transitioned the role of the Quality & Compliance Committee to the Innovation & Quality committee on September 30^th, 2021.

The Innovation & Quality committee will provide oversight of the Company’s focus on accelerating growth through product and process innovation and quality. Natus’ success with investments in research and development to advance patient care, coupled with compliance with quality systems and regulatory requirements related to product safety and efficacy are critical to the achievement of the Company’s strategic growth objectives. Dr. Bryant Moore will chair the Innovation & Quality committee.

The ESG committee will enable the Board to ensure ESG risks and opportunities are integrated into the Company’s strategy; provide oversight of the Company’s on-going commitment to sustainability, human capital development, health & safety, data security, diversity & inclusion, and other ESG pillars; and champion transparency in ESG reporting for shareholders. Alice Schroeder will chair the ESG committee.

“My fellow Board members and I are excited that these two committees heighten the Board’s focus on ESG, Innovation and Quality. These are cornerstones of growth and our efforts to create long-term shareholder value. We look forward to collaborating with Jonathan and the Natus Management Team to continue many existing best practices and implement opportunities to improve at all levels of the Company,” said Joshua Levine, Chairman of the Board. Mr. Levine added, “I would also like to thank Tom Sullivan for assuming the additional responsibilities as Senior Independent Director. With his board and management experience, he is a valuable resource and sounding board for myself and our Directors.”

“The foundation of our business and products centers on improving patients' lives, which is core to our social responsibility and sustainability. Innovating and improving the quality of our products enables Natus to make an impact and contribute to society. We have made noteworthy progress in our ESG initiatives in recent years and recognize that further progress in this area is a journey. We look forward to working with our Board to increase the transparency of our accomplishments and to broaden our sustainability in the future,” said Jonathan Kennedy, President and Chief Executive Officer of Natus.

About Natus Medical Incorporated

Natus Medical Incorporated improves patient outcomes using the most comprehensive product solutions, depth of training and continuing customer care when diagnosing and treating central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical Incorporated can be found at https://natus.com.

Contacts:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com  

FAQ

What is the purpose of the new Environmental, Social & Governance committee at Natus (NTUS)?

The ESG committee aims to integrate ESG risks and opportunities into the company's strategy, oversee sustainability initiatives, and enhance transparency in ESG reporting.

Who chairs the newly formed Innovation & Quality Committee at Natus (NTUS)?

Dr. Bryant Moore chairs the Innovation & Quality Committee, focusing on accelerating growth through product innovation and quality oversight.

What does the transition from Quality & Compliance to Innovation & Quality Committee mean for Natus (NTUS)?

This transition indicates a strategic shift to emphasize innovation and quality in product development, essential for the company's growth objectives.

Who was appointed as Senior Independent Director at Natus (NTUS)?

Thomas J. Sullivan was named Senior Independent Director, bringing valuable experience and governance to the board.